Chimeric Antigen Receptor (CAR)-T cell therapy is a therapeutic approach whereby T-cells are engineered with a synthetic receptor for increased tumor targeting specificity and tumor cytotoxicity.
The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully ...
Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...
70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results